Abstract
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality with both monogenic and polygenic components. We here report results from the largest HCM genome-wide association study (GWAS) and multi-trait analysis (MTAG) including 5,900 HCM cases, 68,359 controls, and 36,083 UK Biobank (UKB) participants with cardiac magnetic resonance (CMR) imaging. We identified a total of 70 loci (50 novel) associated with HCM, and 62 loci (32 novel) as sociated with relevant left ventricular (LV) structural or functional traits. Amongst the common variant HCM loci, we identify a novel HCM disease gene, SVIL, which encodes the actin-binding protein supervillin, showing that rare truncating SVIL variants cause HCM. Mendelian randomization analyses support a causal role of increased LV contractility in both obstructive and non-obstructive forms of HCM, suggesting common disease mechanisms and anticipating shared response to therapy. Taken together, the findings significantly increase our understanding of the genetic basis and molecular mechanisms of HCM, with potential implications for disease management.
Competing Interest Statement
R.T. has received research support from Bristol Myers Squibb. A.R.H. is a current employee and stockholder of AstraZeneca. D.P.O.R. has received grants and consultancy fees from Bayer. R.d.B. has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and also has speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. P.G. receives research funds from Abbott Cardiovascular and Medtronics. C.M.K. received research grants from Cytokinetics and Bristol Myers Squibb. P.M.M. has received consultancy fees from Roche, Biogen, Nodthera and Sangamo Pharmaceuticals and has received research or educational funds from Biogen, Novartis, Merck and Bristol Myers Squibb. J.-C.T. has received research grants from Amarin, AstraZeneca, Ceapro, DalCor, Esperion, Ionis, Novartis, Pfizer and RegenXBio; honoraria from AstraZeneca, DalCor, HLS Therapeutics, Pendopharm and Pfizer; holds minor equity interest in DalCor; and is an author of a patent on pharmacogenomics-guided CETP inhibition. J.S.W. has received research support or consultancy fees from Myokardia, Bristol-Myers Squibb, Pfizer, and Foresite Labs. C.R.B. has consulted for Illumina. H.W. has consulted for Cytokinetics, BridgeBio and BioMarin.
Funding Statement
This work was supported by funding from the British Heart Foundation (BHF, RG/18/9/33887, RE/18/4/34215, FS/15/81/31817); the National Heart, Lung, and Blood Institute (NIH grant U01HL117006-01A1); the Wellcome Trust (201543/B/16/Z, 107469/Z/15/Z, 200990/A/16/Z); the Wellcome Trust core awards (090532/Z/09/Z, 203141/Z/16/Z); the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; the NIHR Imperial College Biomedical Research Centre; NIHR Royal Brompton Cardiovascular Biomedical Research Unit; Sir Jules Thorn Charitable Trust [21JTA]; the Medical Research Council (MRC, UK); the Dutch Heart Foundation (CVON 2018-30 PREDICT2); the Horstingstuit Foundation; the Montreal Heart Institute Foundation; the Philippa and Marvin Carsley Cardiology Chair; the Fonds de la Recherche du Quebec-Sante (254616, 265449); the Canadian Institutes for Health Research (CIHR, 428321). For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed in this work are those of the authors and not necessarily those of the funders. R.T. holds the Canada Research Chair in translational cardiovascular genetics. S.L.Z. received support from BHF Centre of Research Excellence Clinical Research Fellowship (RE/18/4/34215). C.F. received funding from a BHF Clinical Research Training Fellowship (FS/15/81/31817). A.R.H. received support from the MRC Doctoral Training Partnership. X.X. is currently a post-doc scientist funded by MRC-London Institute of Medical Sciences. R.W. received support from an Amsterdam Cardiovascular Sciences fellowship. M.T. receives support from Monat Foundation. S.J.J. was supported by a Junior Clinical Scientist Fellowship (03-007-2022-0035) from the Dutch Heart Foundation, and by an Amsterdam UMC Doctoral Fellowship. Y.M.P. receives support from the Dutch Heart Foundation (CVON PRIME). B.P.H. is funded by the BHF Intermediate Fellowship (FS/ICRF/21/26019). D.P.O.R. is supported by the MRC (MC_UP_1605/13) and BHF (RG/19/6/34387). R.A.d.B. is supported by the Dutch Heart Foundation (2020B005), by the Leducq Foundation (Cure-PLaN), and by the European Research Council (ERC CoG 818715). I.C. receives support from the Dutch Heart Foundation (CVON 2015-12 eDETECT). P.M.M. received funding from the Edmond J. Safra Foundation and Lily Safra and an NIHR Senior Investigator Award, the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the MRC, Alzheimer Society, and Alzheimer Research UK and the Imperial College British Heart Foundation Centre of Excellence. J.-C.T. holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis, and he is also the principal investigator of the Montreal Heart Institute Andre and France Desmarais hospital cohort funded by the Montreal Heart Institute Foundation. A.G. has received support from the BHF, European Commission [LSHM-CT- 2007-037273, HEALTH-F2-2013-601456] and TriPartite Immunometabolism Consortium [TrIC]- NovoNordisk Foundation [NNF15CC0018486], BHF-DZHK (SP/19/2/344612). C.R.B. received support from EJP-RD (LQTS-NEXT, ZonMW project 40-46300-98-19009) and the Leducq Foundation (project 17CVD02). HW is member of the Oxford BHF Centre for Research Excellence (RE/13/1/30181). HW and JW are supported by CureHeart, the British Heart Foundation Big Beat Challenge award (BBC/F/21/220106). This research has been conducted in part using the UK Biobank Resource under application numbers 18545 and 47602. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care), and funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees of the Montreal Heart Institute, Amsterdam University Medical Center, South Central - Hampshire B, Hammersmith & Queen Charlotte, South Central - Oxford A, and East of England - Cambridge South gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 and 5 revised
Data Availability
Data from the Genome Aggregation Database (gnomAD, v.2.1.1) are available at https://gnomad.broadinstitute.org. Data from the UKB can be requested from the UKB Access Management System (https://bbams.ndph.ox.ac.uk). Data from the GTEx consortium are available at the GTEx portal (https://gtexportal.org). Published snRNA-seq data are available at the Broad Single Cell Portal (singlecell.broadinstitute.org) and at the Cellxgene tool website (https://cellxgene.cziscience.com/collections/e75342a8-0f3b-4ec5-8ee1-245a23e0f7cb/private). Other datasets generated during and/or analyzed during the current study can be made available upon reasonable request to the corresponding authors. Individual level data sharing is subject to restrictions imposed by patient consent and local ethics review boards. Summary statistics of GWAS and MTAG will be made available in the GWAS catalog upon publication following peer-review, and interactive Manhattan and regional plots will be made available at www.well.ox.ac.uk/hcm.
